BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//ddaysoftware.com//NONSGML DDay.iCal 1.0//EN
BEGIN:VEVENT
DESCRIPTION:The program will include:\n\nUpdate on faricimab and ranibizuma
 b PDS\nSafety issues with 1.25% pilocarpine (Vuity™\, Allergan/Abbvie)\nBi
 osimilars in retina\nComplement Inhibition Phase 3 discussion\nDiscussion 
 of other issues seen by the ReST Committee and ASRS members\n\nAccreditati
 on Statement and CME Credit\nThe American Society of Retina Specialists is
  accredited by the Accreditation Council for Continuing Medical Education 
 to provide continuing medical education for physicians.\nThe American Soci
 ety of Retina Specialists designates this live activity for a maximum of 1
 .0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit 
 commensurate with the extent of their participation in the activity.\nFina
 ncial Interest Disclosures for ReST Committee
DTEND:20221027T013000Z
DTSTAMP:20260925T025243
DTSTART:20221027T003000Z
LOCATION: \,  
SEQUENCE:0
SUMMARY:Clinical Trials Unplugged: Annual Drug Safety Update (Sponsored by 
 the ReST Committee)
UID:9ceac146-c6cb-451f-8e6f-3bdc5adf4ae3
END:VEVENT
END:VCALENDAR